A recent study from the Department of Laboratory Medicine, University of California San Francisco, San Francisco, California 94143, USA; and Department of Haematology, University of Cambridge, Cambridge CB2 OAH, UK” shows that Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoid leukaemia. This study was published in the 10 March 2015 issue of the Online journal “Nature Communication” by Prof Müschen M, Buchner M and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product–based therapy for leukaemia: Rhamnetin, an O-methylated flavonol isolated from cloves, suppresess B-cell lineage acute lymphoid leukaemia via up regulation of its target gene
This study suggests a natural product-based therapy for human leukaemia: Rhamnetin, by suppressing the expression of its target gene, it may inhibit the progression of B-cell lineage acute leukaemia. Thus, pharmacological formulations encompassing “Rhamnetin or its analogues” may be used to inhibit B-cell lineage acute leukaemia.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Natural product-based therapy for leukaemia: Rhamnetin, an O-methylated flavonol isolated from cloves, suppresses porcine, suppresess B-cell lineage acute lymphoid leukaemia via up regulation of its target gene, 14/June/2015, 6.39 am, Genome-2-Bio-MedicineDiscoverycenter (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org
* Research cooperation
Undisclosed information: How Rhamnetin inhibits the progression of B-cell lineage acute lymphoid leukaemia.